Latest Conference Articles

Samsung Bioepis Shares 1-Year Phase 3 Results for Eylea Biosimilar

Skylar Jeremias

May 2 2023

At the 2023 Association for Research in Vision and Ophthalmology Annual Meeting, Samsung Bioepis shared comparable safety, efficacy, and immunogenicity data through 1 year between its aflibercept biosimilar (SB15) and the originator (Eylea).

Favorable Equivalency Studies of Candidate Biosimilar AVT04 and Reference Ustekinumab

Justina Petrullo

March 27 2023

Posters presented by Alvotech at 2023 American Academy of Dermatology (AAD) annual meeting showcased proven bioequivalence and therapeutic equivalence candidate biosimilar AVT04 and reference ustekinumab (Stelara).

Getting Ophthalmic Biosimilars to Market Continues to Prove Difficult

Maggie L. Shaw

March 27 2023

Representatives from Magellan Rx Management provided a detailed overview of current treatment options in ophthalmology and the impact that biosimilars could have during a session at AMCP 2023.

A Long Time Coming: Dr Sophia Humphreys Details What’s Coming Down the Biosimilar Pipeline

Skylar Jeremias

March 23 2023

In the wake of adalimumab biosimilars hitting the US market, Sophia Z. Humphreys, PharmD, MHA, BCBBS, of Sutter Health, hyped up the current biosimilar market trends and the other products coming down the pipeline during her talk at the Festival of Biologics.

Published Data Coupled With Real-world Evidence Show Safety of Biosimilar-to-Biosimilar Switching

Skylar Jeremias

March 22 2023

At the Festival of Biologics, Hillel Cohen, the executive director of scientific affairs at Sandoz, shared the current body of literature on biosimilar-to-biosimilar switching, saying that although there isn’t much published data, the vast real-world experience demonstrates the safety of this type of medication switch.

Uptake Barriers Will Deter Future Competitors From Investing in Biosimilars, Julie Reed Warns

Skylar Jeremias

March 21 2023

At the Festival of Biologics, Juliana (Julie) Reed, executive director of the Biosimilars Forum, warned that without changes to encourage biosimilar uptake, companies will begin to ask the big question: Are biosimilars worth investing in?

Samsung Bioepis’ Stelara Biosimilar Proves Successful in Phase 1 Study

Skylar Jeremias

March 20 2023

At the American Academy of Dermatology annual meeting, Samsung Bioepis shared positive results from a phase 1 study comparing its ustekinumab biosimilars (SB17) with the reference product (Stelara).

IQVIA's Michael Kleinrock Shares Why Smaller Manufacturers Are Investing in Biosimilar Development

Skylar Jeremias

March 12 2023

Better familiarity with biosimilars is enabling government agencies to reevaluate their approval requirements and encouraging smaller manufacturers to invest in biosimilar development, said Michael Kleinrock, lead research director for the IQVIA Institute for Human Data Science.

Celltrion Publishes Data on Maintenance Therapy Using Infliximab Biobetter

Skylar Jeremias

March 6 2023

At the European Crohn’s and Colitis Organisation congress, Celltrion Healthcare shared positive safety and efficacy data on maintenance therapy including its infliximab biobetter allowing for subcutaneous administration, Remsima SC.

Access 2023: FDA’s Dr Jacqueline Corrigan-Curay Gives Updates on Biosimilar, Generic User Fee Programs

Skylar Jeremias

February 22 2023

Jacqueline Corrigan-Curay, MD, JD, principal deputy center director of the FDA's Center for Drug Evaluation and Research, gave a keynote presentation at Access 2023 on how the Biosimilar User Fee Act and the Generic Drug User Fee Act have developed over the last year.